You'd think with the massive staffing spend that someone might have some capacity...
The real reason the p1b was terminated is likely because it wasn't competitive with Keytruda et al which all go off patent the next few years.
The market has already moved past PD-1/PD-L1 (only) inhibitors. The reality is you've got to dominate the market. None of IMU's programs look set to achieve that.
Eg.
IMU Price at posting:
1.5¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)